CRISPR Therapeutics AG (CRSP)

Market Cap	2.96B
Revenue (ttm)	37.68M
Net Income (ttm)	-385.66M
Shares Out	86.36M
EPS (ttm)	-4.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,119,121
Open	34.51
Previous Close	33.16
Day's Range	33.50 - 34.64
52-Week Range	30.04 - 67.88
Beta	1.87
Analysts	Buy
Price Target	74.06 (+116.23%)
Earnings Date	May 6, 2025

About CRSP

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 19, 2016
• Employees: 393
• Stock Exchange: NASDAQ
• Ticker Symbol: CRSP
• Website: https://www.crisprtx.com

Financial Performance

In 2024, CRISPR Therapeutics AG's revenue was $37.31 million, a decrease of -89.95% compared to the previous year's $371.21 million. Losses were -$366.25 million, 138.4% more than in 2023.

Analyst Forecast

According to 19 analysts, the average rating for CRSP stock is "Buy." The 12-month stock price forecast is $74.06, which is an increase of 116.23% from the latest price.

Price Target

$74.06

(116.23% upside)

Analyst Consensus: Buy